Sodium Glucose Co-Transporter 2 Inhibitors in Patients With Heart Failure and Transcatheter Aortic Valve Replacement.

ABSTRACT:

Background

Patients undergoing transcatheter aortic valve replacement (TAVR) have a high risk of adverse cardiovascular outcomes due to comorbid conditions such as congestive heart failure (CHF). Recent trials show promising results of sodium glucose co-transporter 2 inhibitors in CHF patients.

Objectives

In this observational cohort study, we aim to explore the cardiovascular outcomes of SGLT2 inhibitors vs standard care in CHF patients undergoing TAVR using a large research network database.

Methods

A retrospective cohort analysis of deidentified, aggregate patient data from the TriNETX research network was conducted. Subjects with CHF who underwent a TAVR procedure, were ≥18 years old, and received either SGLT2 inhibitors or standard of care were included in the an

SUBMITTER: Yasmin F 

PROVIDER: S-EPMC12856177 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature